Radionuclide therapy

26
8 Radionuclide therapy

description

8. Radionuclide therapy. Principles of radionuclide therapy “ . - PowerPoint PPT Presentation

Transcript of Radionuclide therapy

Page 1: Radionuclide therapy

8

Radionuclide therapy

Page 2: Radionuclide therapy

The therapeutic use of radiopharmaceuticals is based on the concept of selective localization of radiopharmaceuticals coupled with the lethality of the same because of the tissue damage resulting from highly ionizing particulate emissions such as β particles.

Principles of radionuclide therapy �

Page 3: Radionuclide therapy

Principles of radionuclide therapy �The radionuclide has to be concentrated at the site of the abnormality (tumor) with minimal injury to the normal tissues

A variety of approaches to this problem is possible

1- Element e.g. I-131, P-32, Sr-892-Metabolic agents, e.g. I-131 MIBG3-Labeled antibodies4-Labeled cell5- Direct administration into the cavities

Page 4: Radionuclide therapy

Tissue factors affecting rardiopharmaceutical uptake

1- blood perfusion 2-exravascular space 3-interstitial pressure

Reduction in blood flow causes -Less radiopharmaceutical is supplied to the viable cell -Hypoxic state of the cells reduces the effect of the radiation (Hypoxic cells are resistant)

Page 5: Radionuclide therapy

Principles of radionuclide therapy

1-Radiopharmaceutical uptake (%) 2-Quantity of radiopharmaceutical 3-Retention of radiopharmaceutical 4-Physical half-life- Too short will not take full advantages of the time in the tissue- Long time gives unnecessary radiation dose to normal tissues

5-Non-homogenous uptake reduces local absorbed dose

6-selectivety of radiopharmaceutical (target to non target)

Page 6: Radionuclide therapy

Radionuclides therapy

ParticleAlpha emitters ( short range: 50 µm) rarely usedBeta emitters (I-131, P-32,Sr-89; range few mm) most commonly used

Gamma rays (I-125)

Page 7: Radionuclide therapy
Page 8: Radionuclide therapy
Page 9: Radionuclide therapy
Page 10: Radionuclide therapy

* Thyroid I-131 Radionuclide therapy Thyrotoxicosis Differentiated thyroid cancers * P-32 therapy in myeloproliferative diseases Polycycemia rubra vera * MIBG therapy neuroblastomaand phaeochromocytomaand

* Therapeutic use of radiolabelled antibodies (Target)

* Palliation of bone pain (Strontium-89 and Smarium-153) bone metastases of breast and prostate

Page 11: Radionuclide therapy

Alternative approaches to targeting therapy

Injection into serous cavities-Intra-peleural therapy-Intra-peritoneal cavity -Intra-articular therapy-Direct intra-cystic injection

Page 12: Radionuclide therapy

The thyroid Thyrotoxicosis Differentiated thyroid cancers RAI I-131 Half life 8 Principal gamma energies 360keV Principal beta Emax 0.6 MeV In the past 60 years many patients through out the world have received treatment for both thyrotoxicosisand thyroid carcinoma and the cumulative experience with this form of radionuclide therapy has confirmed its safety and efficacy

Page 13: Radionuclide therapy

Therapy of thyrotoxicosis1-Medical2-Surgery3-RAI

Causes of ThyrotoxicosisDiffuse toxic goiter (Graves´ disease)Multinodular goiter (Plummer’s disease)Toxic autonomous nodule

Page 14: Radionuclide therapy

Practical aspects of RAI therapy in thyrotoxicosis Before RI therapy it is essential that :1-the diagnosis of thyrotoxicosis has been confirmed both clinically and biochemically (hormonal assay T3,T4,and TSH)

2-The use of radionuclide scan in the diagnosis of patients with thyrotoxicosis is very important: a-It confirms the nature of the thyrotoxicosis b- Graves’disease versus multinodular goiter Plummer’s disease c- % thyroid uptake

Page 15: Radionuclide therapy

RAI therapy for thyrotoxicosis General consensus* It is an appropriate treatment for men and women of the middle age upwards (not usually preferred in young age)

*There is no demonstrable risk associated with RAIadministration

*No increased incidence of leukemia and thyroid malignancies * No increased incidence of genetic defects in children born to women and man treated with RAI

Page 16: Radionuclide therapy

Importance of RAI therapy in thyrotoxicosis

Radioiodine would appear from all available data to be safe of treatment in all patients groups including:women of child-bearing years and children but excluding women who arepregnant and breastfeeding

Prior to RAI therapy in thyrotoxicosis -Generally elderly patients with thyrotoxicosis should be rendered euthyroid prior to therapy to avoid unpleasant exacerbation of thyrotoxicosis-Prior to RI therapy antithyroiddrug should be discontinued for several days to ensure adequate trapping of RAI

Page 17: Radionuclide therapy

Treatment dose, radiation dose and outcome

The usual administrated dose ranges from 10mCi-20mCi (adult dose 10 mCi)

The radiation dose received by family members is low but itis proportional to the close contacttime such as meal times, car travel and sleeping in a double bed

The incidence of hypothyroidism in the first year ranges between 10-25% with an annual increment, depending on the amount of the administrated dose

Page 18: Radionuclide therapy

Side effects of RI treatment

-Hypothyroidism-Exacerbation of thyrotoxicosis at 7-10 days following RAI administration-Sialitis( the symptoms are usually short lived)-Alterations in taste-Radioiodine is not contra indicated in patients with dysthyroid eye disease

Page 19: Radionuclide therapy

Thyroid carcinoma

Pathology

* Well Differentiated thyroid Carcinoma (WDTC) Papillary Follicular mixed Papillary and Follicular *Anaplastic ( 5%) *Medullary (10%)

- WDTC in general take up RAI -Nodal metastases are presented at diagnosis in 36% of patients with papillary ca and 13% of patients with follicular ca- Distant metastases were associated with 4% of papillary ca and 16% of follicular ca

Page 20: Radionuclide therapy

Treatment of thyroid cancer Surgery total or near total thyroidectomyFollowing surgical treatment RAI is the essential treatment

RI has three major roles:- Diagnosis- Ablation- Treatment

Page 21: Radionuclide therapy

Diagnosis

The initial diagnostic approach following surgery is the demonstration of residual normal thyroid tissuefollowing the removal of thyroid tumor Thyroid whole body iodine scans is performed to localize remnant thyroid tissue

Thyroid remnant ablationSubsequent administration of therapy doses will be more effective if all normal thyroid tissue is ablated

The ablation doses are between 30-200mCi

Page 22: Radionuclide therapy
Page 23: Radionuclide therapy

- Patients should be hospitalized into a special room until the level of activity fall below that permitted for discharge

- Following ablation the patient should be maintained on thyroxine replacement treatment

- Six months after thyroxine should be discontinued and the patient is reevaluated with I-131 whole body scan

- If recurrent is demonstrated the patient should be admitted for a therapy doseof RAI

Page 24: Radionuclide therapy

- The therapy dose will usually vary from 150-200mCi of RAI

- After treatment the patient returned back on thyroxine replacement therapy

- A repeat scan will be performed following an interval of 6-12months

- Further therapy is given when necessary

Page 25: Radionuclide therapy

Side effects of radioiodinetherapy

-Nausea-Radiation thyroiditis-Acute and/or chronic sialadenitis-Oligospermiaor azoospermia(70%)-There are no reports in the literature of infertility, or congenital abnormalities in children treated with RAI for thyroid carcinoma

Page 26: Radionuclide therapy

Thank you and Good Luck

Prof. Dr. Omar Shebl Zahra